Who are Tyrosine kinase inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inlyta, DW6012(Dasidiem tab. 10/100mg), Dasatinib Tablets, Cipterbin Combined With Vinorelbine, Anlotinib plus Pemetrexed, Axitinib (AG-013736).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tyrosine-kinase-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tyrosine kinase inhibitor — Competitive Intelligence Brief

Tyrosine kinase inhibitor (Tyrosine kinase inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tyrosine kinase inhibitor (Tyrosine kinase inhibitor) — Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tyrosine kinase inhibitor TARGET	Tyrosine kinase inhibitor	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	phase 3	Tyrosine kinase inhibitor
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Dasatinib Tablets	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
Cipterbin Combined With Vinorelbine	Cipterbin Combined With Vinorelbine	Zhejiang Cancer Hospital	marketed	Tyrosine kinase inhibitor combined with vinca alkaloid	Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine)
Anlotinib plus Pemetrexed	Anlotinib plus Pemetrexed	Henan Provincial People's Hospital	marketed	Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite	VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed)
Axitinib (AG-013736)	axitinib-ag-013736	Pfizer	marketed	tyrosine kinase inhibitor	vascular endothelial growth factor receptors (VEGFRs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tyrosine kinase inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/tyrosine-kinase-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab